Tango Therapeutics Inc（TNGX）の財務TNGXTango Therapeutics Inc

Evaluating the bottom line, Tango Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -21.34%, provide a clear picture of how effectively TNGX converts its operational activities into shareholder value.

In the context of the broader market, TNGX competes directly with industry leaders such as RLAY and ABCL. With a market capitalization of $3.94B, it holds a significant position in the sector. When comparing efficiency, TNGX's gross margin of N/A stands against RLAY's 100.00% and ABCL's 100.00%. Such benchmarking helps identify whether Tango Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Tango Therapeutics has shown a gross margin of 100% in recent quarters, indicating strong potential profitability on sales, although they have reported net losses in several quarters.